Valeant Discusses Strategy, Reflects On Four Years Of Growth
This article was originally published in The Pink Sheet Daily
True to form, the contrarian CEO of Valeant tells analysts that his company favors investment in business development over share buybacks, out-of-the spotlight emerging markets (Southeast Asia, South Africa, and Eastern and Central Europe), and niche therapeutic areas like dermatology and ophthalmology, all largely cash markets, where Valeant can stress its brand and distribution capabilities over scientific innovation.
You may also be interested in...
Novo Nordisk and Allergan both report setbacks during their respective first quarter earnings calls. Meanwhile, Valeant and Actavis avoid speculation about a potential merger, and other Q1 happenings.
The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.
The specialty pharma is gearing up for as many as four more "tuck-in" acquisitions after completing a reverse-merger with Biovail and acquiring PharmaSwiss.